Oral glucose tolerance test (OGTT) for T1D staging
What it is
The metabolic staging test that turns a positive autoantibody screen into an actionable stage-1 vs stage-2 risk assessment. It is burdensome compared with home blood spots, but remains the guidance-described gold-standard way to detect dysglycemia and qualify people for monitoring, trials, or approved stage-2 therapy.
Editorial review: .
Most recent recorded citation date: 2025-07-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Predictive value: Consensus guidance treats OGTT as the gold-standard metabolic test for accurately classifying early-stage T1D and detecting stage-2 dysglycemia.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 55 × 20 + 88 × 25 + 85 × 25 + 35 × 15 = 5950; divide by total weight 85. Unrounded weighted result: 70.
Available as a clinical test, but harder to scale than mailed capillary autoantibody screening because it requires fasting, timed samples and clinic/lab workflow.[1]
Consensus guidance treats OGTT as the gold-standard metabolic test for accurately classifying early-stage T1D and detecting stage-2 dysglycemia.[1]
Abnormal OGTT results can move a person from stage 1 to stage 2, changing monitoring intensity, trial eligibility and access to approved disease-modifying therapy.[2]
The test is time-consuming and inconvenient compared with home sampling, making it a targeted follow-up/staging test rather than the first-line population screen.[1]
Editor’s take
OGTT is the unsexy hinge between screening and action. Autoantibodies tell you the immune process has started; OGTT helps decide whether glucose has already begun to fail. The field still needs lower-burden substitutes, but today OGTT is the staging workhorse.
The full picture
The test after the screen
Autoantibody screening finds people whose immune system is already targeting their beta cells. OGTT answers the next question: has glucose regulation started to fail? That distinction matters because stage 1 is autoantibodies with normal glucose, while stage 2 adds dysglycemia. Stage 2 is where monitoring tightens and where approved therapy such as teplizumab can become relevant.
Why it is not the first screen
OGTT is accurate but inconvenient: fasting, a glucose drink, and timed blood draws. That makes it a follow-up and staging tool, not the scalable front door. The practical model is home or capillary autoantibody screening first, OGTT for people who need metabolic staging.
Sources
- [1]Consensus Guidance for Monitoring Individuals With Islet Autoantibody- Positive Pre-Stage 3 Type 1 Diabetes · Peer-reviewed study · 2024-06-24 — International guidance on monitoring autoantibody-positive people before stage-3 T1D; identifies OGTT as the gold-standard metabolic staging tool.
- [2]TrialNet Pathway to Prevention of T1D · Trial registry · 2025-07-01 — Registry describes OGTT at eligibility/monitoring visits for multiple autoantibody-positive participants.